Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2018 09:25 ET | Source: Endocyte, Inc.

Endocyte Stockholders Approve Merger Agreement with Novartis AG

WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced...
November 07, 2018 16:01 ET | Source: Endocyte, Inc.

Endocyte Provides Third Quarter 2018 Financial Results and Operational Update

Entered into agreement and plan of merger with Novartis AG for $2.1Billion WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical...
October 18, 2018 01:10 ET | Source: Endocyte, Inc.

Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion

Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE...
September 27, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte to Present at Two Investor Conferences on October 2nd

WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
September 14, 2018 16:01 ET | Source: Endocyte, Inc.

Endocyte Announces Closing of Public Offering of Common Stock

WEST LAFAYETTE, Ind., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
September 11, 2018 19:53 ET | Source: Endocyte, Inc.

Endocyte Announces Pricing of Public Offering of Common Stock

WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
September 10, 2018 16:15 ET | Source: Endocyte, Inc.

Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock

WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,...
September 10, 2018 08:00 ET | Source: Endocyte, Inc.

Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)

Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval A positive assessment on either rPFS or OS is sufficient for full approval rPFS analysis...
August 29, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference

WEST LAFAYETTE, Ind., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
August 28, 2018 17:04 ET | Source: Endocyte, Inc.

UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018

WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...